当前位置: 首页 > 期刊 > 《中国医学创新》 > 2019年第17期
编号:13370836
川芎嗪对创伤性颅脑损伤大鼠的保护作用及机制研究(5)
http://www.100md.com 2019年6月15日 《中国医学创新》 2019年第17期
     [14] Chen K J,Chen K.Ischemic stroke treated with Ligusticum chuanxiong[J].Chin Med J(Engl),1992,105(10):870-873.

    [15] Tsai T H,Liang C.Pharmacokinetics of tetramethylpyrazine in rat blood and brain using microdialysis[J].Int J Pharm,2001,216(1-2):61-66.

    [16] Jiang Y R,Chen K J.Pharmacological roles of ligustrazine in cardio-/cerebrovascular systems and its progress in researches of clinical application[J].Zhongguo Zhong Xi Yi Jie He Za Zhi,2013,33(5):707-711.

    [17] Zhao T,Fu Y,Sun H,et al.Ligustrazine suppresses neuron apoptosis via the Bax/Bcl-2 and caspase-3 pathway in PC12 cells and in rats with vascular dementia[J].IUBMB Life,2018,70(1):60-70.

    [18] Liu S Y,Sylvester D M.Antithrombotic/antiplatelet activity of tetramethylpyrazine[J].Thromb Res,1990,58(2):129-140.

    [19] Liu S Y,Sylvester D M.Antiplatelet activity of tetramethylpyrazine[J].Thromb Res,1994,75(1):51-62.

    [20] Shen T,Xu H,Weng W,et al.Single- and multiple-dose pharmacokinetics of a novel tetramethylpyrazine reservoir-type transdermal patch versus tetramethylpyrazine phosphate oral tablets in healthy normal volunteers,and in vitro/in vivo correlation[J].Biol Pharm Bull,2013,36(6):931-937.

    (收稿日期:2019-02-13) (本文編辑:张爽), 百拇医药(易润青 全向阳)
上一页1 2 3 4 5